| Estrella Resources Limited (ESR) ORDINARY FULLY PAID |
Materials |
$68 |
Estrella Mobilises and Commences Drilling Timor-Leste
|
29 May 2025 8:56AM |
$0.033 |
$0.031 |
fallen by
6.06%
|
|
ESR - Price-sensitive ASX Announcement
Full Release
Key Points
- Estrella Resources Limited (ESR) has commenced drilling operations in Timor-Leste.
- The company has mobilised resources and equipment to the project site.
- Initial drilling targets have been identified within granted tenement areas.
- Logistical and regulatory preparations were completed prior to commencement.
- ESR is engaging with local communities and stakeholders for smooth operations.
- The company is focusing on responsible exploration and environmental compliance.
- Drilling activities are aimed at evaluating mineral resource potential.
- ESR is committed to transparency and ongoing stakeholder communication.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Andromeda Metals Limited (ADN) ORDINARY FULLY PAID |
Materials |
$60 |
Notice of General Meeting/Proxy Form
|
29 May 2025 8:55AM |
$0.010 |
$0.013 |
risen by
30%
|
|
| Invion Limited (IVX) ORDINARY FULLY PAID |
Health Care |
$8 |
Encouraging SRC Findings on Ph I/II Skin Cancer Trial
|
29 May 2025 8:53AM |
$0.085 |
$0.090 |
risen by
5.88%
|
|
IVX - Price-sensitive ASX Announcement
Full Release
Key Points
- Invion Limited announced positive interim results from its Phase I/II skin cancer trial for IVX-PDT.
- The trial focuses on patients with non-melanoma skin cancer, primarily BCC and SCC.
- IVX-PDT demonstrated good safety and was well tolerated by trial participants.
- No significant adverse events were reported during the trial.
- A high percentage of treated lesions exhibited positive clinical response.
- Findings support further clinical development and expansion of IVX-PDT for skin cancer.
- The results are in line with Invion's strategy to explore broader oncological applications of its photodynamic therapy platform.
- The company is encouraged by the interim data and will continue to monitor and report on trial progress.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$122 |
Cleansing Notice
|
29 May 2025 8:52AM |
$0.220 |
$0.455 |
risen by
106.82%
|
|
| Macquarie Group Limited (MQG) ORDINARY FULLY PAID |
Financials |
$78,145 |
Issue of A$1.25bn subordinated notes cleansing notice
|
29 May 2025 8:52AM |
$209.990 |
$205.030 |
fallen by
2.36%
|
|
| Duxton Water Limited (D2O) ORDINARY FULLY PAID |
Utilities |
$238 |
Update - Notification of buy-back - D2O
|
29 May 2025 8:50AM |
$1.535 |
$1.530 |
fallen by
0.33%
|
|
| EDU Holdings Limited (EDU) ORDINARY FULLY PAID |
Consumer Discretionary |
$119 |
Withdrawal of Proposed Delisting and Equal Access Buy-back
|
29 May 2025 8:50AM |
$0.200 |
$0.825 |
risen by
312.50%
|
|
EDU - Price-sensitive ASX Announcement
Full Release
Key Points
- EDU Holdings Limited has withdrawn its proposed delisting from the ASX.
- The planned equal access buy-back has also been withdrawn.
- The decision was made after considering stakeholder feedback and regulatory factors.
- EDU Holdings will remain listed on the ASX.
- The company remains focused on its core business and long-term strategy.
- Shareholders were thanked for their engagement and input.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| West Coast Silver Limited (WCE) ORDINARY FULLY PAID |
Materials |
$81 |
Updated Top 20 Shareholders
|
29 May 2025 8:49AM |
$0.054 |
$0.245 |
risen by
353.70%
|
|
| PlaySide Studios Limited (PLY) ORDINARY FULLY PAID |
Communication Services |
$115 |
Notification of cessation of securities - PLY
|
29 May 2025 8:49AM |
$0.135 |
$0.255 |
risen by
88.89%
|
|
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$122 |
Application for quotation of securities - ILA
|
29 May 2025 8:48AM |
$0.220 |
$0.455 |
risen by
106.82%
|
|
| Whitehaven Coal Limited (WHC) ORDINARY FULLY PAID |
Energy |
$6,508 |
Update - Notification of buy-back - WHC
|
29 May 2025 8:48AM |
$5.680 |
$7.860 |
risen by
38.38%
|
|
| Biome Australia Limited (BIO) ORDINARY FULLY PAID |
Consumer Staple |
$96 |
Investor Webinar
|
29 May 2025 8:47AM |
$0.410 |
$0.430 |
risen by
4.88%
|
|
| Tesoro Gold Ltd (TSO) ORDINARY FULLY PAID |
Materials |
$234 |
New Gold Zones intercepted at Ternera
|
29 May 2025 8:44AM |
$0.024 |
$1.315 |
risen by
5,379.17%
|
|
TSO - Price-sensitive ASX Announcement
Full Release
Key Points
- Tesoro Gold Ltd discovered new gold zones at the Ternera deposit, El Zorro Gold Project, Chile.
- Drilling identified significant gold intercepts outside the existing resource envelope.
- New gold mineralization zones were intersected to the north and west of the known Ternera resource.
- Infill drilling within current resource areas also returned high-grade gold intercepts.
- The new results indicate significant potential to increase the Ternera gold resource.
- Ongoing drilling and exploration continue to target expansion of the mineralized footprint.
- The announcement reinforces Ternera’s status as a growing and high-potential gold deposit.
- Details of the drilling results include both new and infill zones, with notable gold grades and widths.
- Tesoro Gold Ltd plans to continue aggressive exploration and resource growth efforts at Ternera.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,938 |
Appendix 3C
|
29 May 2025 8:40AM |
$51.020 |
$44.810 |
fallen by
12.17%
|
|
| Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID |
Health Care |
$245 |
FY25 Full Year Results Presentation
|
29 May 2025 8:40AM |
$0.470 |
$0.710 |
risen by
51.06%
|
|
ARX - Price-sensitive ASX Announcement
Full Release
Key Points
- Record revenue growth and improved gross margin reported for FY25.
- Net loss reduced significantly compared to previous year.
- Strong demand for proprietary wound care and tissue reconstruction products.
- Expansion of US commercial operations and direct sales team.
- Launched new product lines and expanded product indications.
- Progress in clinical trials and regulatory approvals.
- Strategic focus on further US market expansion and operational efficiency.
- Continued investment in research and development for pipeline products.
- Solid balance sheet position with positive cash flow from operations.
- Outlook for FY26 includes increased revenue guidance and margin improvements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID |
Health Care |
$245 |
FY25 Appendix 4E and Full Year Results
|
29 May 2025 8:39AM |
$0.470 |
$0.710 |
risen by
51.06%
|
|
ARX - Price-sensitive ASX Announcement
Full Release
Key Points
- Record revenues with double-digit percentage growth over the prior year.
- Substantial reduction in net loss compared to the previous year.
- Positive operating cashflow achieved for the first time.
- Strong performance of key products, particularly in the US market.
- Enhanced gross margins and effective cost control measures implemented.
- Ongoing investments in research and development for new product innovations.
- Progress in regulatory submissions and new product approvals.
- Expansion of the commercial team to drive sales and market presence.
- Focus on sustainable growth, profitability, and global market expansion.
- Outlook remains positive with expectations of further revenue and margin improvements in the coming financial year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,938 |
Appendix 3C
|
29 May 2025 8:39AM |
$51.020 |
$44.810 |
fallen by
12.17%
|
|
| Carlton Investments Limited (CIN) ORDINARY FULLY PAID |
Financials |
$912 |
Notification of cessation of securities - CIN
|
29 May 2025 8:38AM |
$33.910 |
$34.570 |
risen by
1.95%
|
|
| Truscreen Group Limited (TRU) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Health Care |
$10 |
Trading Halt
|
29 May 2025 8:37AM |
$0.027 |
$0.014 |
fallen by
48.15%
|
|
TRU - Price-sensitive ASX Announcement
Full Release
Key Points
- Truscreen Group Limited (NZX:TRU) requested a trading halt on 14 June 2024.
- The trading halt affects Truscreen's ordinary shares on the NZX Main Board.
- The halt is pending the release of an announcement by the company.
- The halt will remain until the announcement is made or until market opens on 18 June 2024.
- No additional details about the announcement or the reasons for the halt are provided in this notice.
- The request is a standard procedural action in anticipation of company news.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$26 |
Green light for HERACLES clinical trial
|
29 May 2025 8:37AM |
$0.066 |
$0.088 |
risen by
33.33%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- Noxopharm Limited received HREC approval to commence the HERACLES clinical trial.
- HERACLES is a Phase 1 study targeting non-muscle invasive bladder cancer.
- The trial will evaluate SOFRAH™, Noxopharm’s lead product candidate.
- Recruitment for the HERACLES trial is planned to commence in mid-2024 in Australia.
- The trial will assess the safety, tolerability, and preliminary efficacy of SOFRAHâ„¢.
- SOFRAHâ„¢ is being developed as a novel immunotherapy option for cancer patients.
- The approval marks a significant milestone in Noxopharm’s clinical development.
- Noxopharm is focusing on expanding its clinical program and advancing novel therapeutics.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Copper Search Limited (CUS) ORDINARY FULLY PAID |
Materials |
- |
Entitlement Offer Prospectus
|
29 May 2025 8:33AM |
$0.018 |
$0.018 |
fallen by
0%
|
|
CUS - Price-sensitive ASX Announcement
Full Release
Key Points
- Copper Search Limited (CUS) is conducting a pro-rata non-renounceable entitlement offer to raise up to $2.4 million.
- The purpose of the capital raising is to fund exploration activities, provide working capital, and cover the costs associated with the offer.
- The offer allows eligible shareholders to subscribe for new shares at a specified price, with the terms and conditions set out in the prospectus.
- Details of eligibility, application process, and allotment procedures are provided to guide participating shareholders.
- The document outlines key risks associated with the investment, including exploration, market, and operational risks.
- Information about the board of directors, management team, and corporate governance is presented.
- The prospectus includes relevant legal, regulatory, and ASX disclosure requirements.
- Timetable and important dates related to the entitlement offer are disclosed.
- Potential impacts on shareholding structure and dilution are discussed.
- Details on how the raised funds will be allocated between exploration, working capital, and offer costs are specified.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| FleetPartners Group Limited (FPR) ORDINARY FULLY PAID |
Financials |
$622 |
Update - Notification of buy-back - FPR
|
29 May 2025 8:32AM |
$3.000 |
$2.880 |
fallen by
4%
|
|
| AMP Limited (AMP) ORDINARY FULLY PAID |
Financials |
$4,608 |
Updated reporting dates and investor session details
|
29 May 2025 8:31AM |
$1.255 |
$1.820 |
risen by
45.02%
|
|
| Cadence Opportunities Fund Limited (CDO) ORDINARY FULLY PAID |
Financials |
$30 |
Update - Notification of buy-back - CDO
|
29 May 2025 8:31AM |
$1.600 |
$1.905 |
risen by
19.06%
|
|
| Thorney Opportunities Ltd (TOP) ORDINARY FULLY PAID |
Financials |
$115 |
Update - Notification of buy-back - TOP
|
29 May 2025 8:28AM |
$0.630 |
$0.670 |
risen by
6.35%
|
|